TENAX THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
TENAX THERAPEUTICS, INC. (TENX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.33 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-07-31
- TENAX THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.33M, a 27.75% decline year-over-year.
- TENAX THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.84M, a 31.48% decline year-over-year.
- TENAX THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $5.62M, a 37380.00% increase year-over-year.
- TENAX THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $4.61M, a 20850.00% increase year-over-year.
- TENAX THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $19.16M, a 1603.38% increase from fiscal 2024.
- TENAX THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.13M, a 489.01% increase from fiscal 2023.
- TENAX THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $191.00K.
- TENAX THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $252.65K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.33M 10-Q · filed 2026-07-31 | $6.17M derived: sum of 2 quarters · filed 2026-07-31 | ||
| 2026-03-31 | $2.84M 10-Q · filed 2026-07-31 | |||
| 2025-12-31 | $19.16M 10-K · filed 2026-03-10 | |||
| 2025-09-30 | $5.62M 10-Q · filed 2025-11-12 | $10.23M derived: sum of 2 quarters · filed 2026-07-31 | $14.37M derived: sum of 3 quarters · filed 2026-07-31 | |
| 2025-06-30 | $4.61M 10-Q · filed 2026-07-31 | $8.75M derived: sum of 2 quarters · filed 2026-07-31 | ||
| 2025-03-31 | $4.14M 10-Q · filed 2026-07-31 | |||
| 2024-12-31 | $1.13M 10-K · filed 2026-03-10 | |||
| 2024-09-30 | $15.00K 10-Q · filed 2025-11-12 | $37.00K derived: sum of 2 quarters · filed 2025-11-12 | $156.00K derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $22.00K 10-Q · filed 2025-11-12 | $141.00K derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $119.00K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $191.00K 10-K · filed 2025-03-25 | |||
| 2020-12-31 | $252.65K 10-K/A · filed 2021-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |